Device Trial Radar · NCT06833060
Transscleral Selective Laser Trabeculoplasty Project
Last checked: Nov 20, 2026Latest source record: Aug 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Jun 19, 2025
Primary completion
Jul 30, 2026
Study completion Jul 30, 2026
Sponsor
- Lead sponsor
- Lumibird Medical (Quantel Medical, Ellex Medical, Optotek)Not on our public-company list
- Sponsor type
- Industry
- Collaborators
- Quantel Medical
- First posted
- Feb 18, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical trial is to determine how safe and effective (how well it works) the ELLEX TSLT device is for the treatment of Glaucoma and Ocular Hypertension using Transscleral Selective Laser Trabeculoplasty. Selective Laser Trabeculoplasty (SLT) is a type of laser therapy that uses short pulses of low-energy light to lower eye pressure. This treatment uses a lens in contact with the front part of the eye (called cornea) which may lead to complications. Transscleral Selective Laser Trabeculoplasty allows the doctor to perform the laser treatment without the lens coming into contact with the cornea, potentially offering a simpler, quicker and safer approach for both participants and doctors. Participants will be required to attend four study visits. The first visit will assess the disease, the second will involve the TSLT laser treatment for the participant's condition (glaucoma or ocular hypertension), and the final two visits, at 1 day and 30 days post-treatment, will evaluate the treatment's efficacy and the procedure's safety.
Conditions
- Glaucoma,Open-Angle
- Ocular Hypertension (OH)
Interventions
Selective Laser TrabeculoplastyDevice
Treatment of Glaucoma or Ocular Hypertension participants using Transscleral Selective Laser Trabeculoplasty
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency of Treatment-Related Adverse EventsTime frame: From treatment to 30 days after
1 more outcomes with a free account
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Central Adelaide Local Health Network - Royal Adelaide Hospital
Adelaide, South Australia, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.